Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies
Molecular Pharmaceutics · 04.09.2023 · 20 (9) · 4714-4728
DOI: 10.1021/acs.molpharmaceut.3c00454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 31.07.2023. Verfasst von Mayank Handa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow 226002, India. Hauptthemen laut MEDLINE: Memantine, Nanoparticles. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers, India.
Abstract (Originalsprache)
This work focuses on developing nanoemulsions using a low-energy emulsification method for the codelivery of donepezil and memantine in one dosage form intended to be administered via the intranasal route for enhanced brain delivery. The nanoemulsion formulation was prepared using a low emulsification technique and characterized using various microscopy and nasal ciliotoxicity studies. The safe nanoemulsion was intended for preclinical pharmacokinetics with brain distribution and pharmacodynamics in a scopolamine-induced murine model. The formulated nanoemulsion was 16 nm in size, with a zeta potential of -7.22 mV, and exhibited a spherical shape. The brain concentration of IN-administered NE for DPZ and MEM was ∼678 and 249 ng/mL after 15 min. This concentration is more than 2 times higher in amount when compared with NE administered via PO, free drug solution administered via IN and PO route both. However, the plasma concentration of IN-administered NE for DPZ and MEM was ∼3 and 28 ng/mL after 15 min. In pharmacodynamic studies, the efficacy of NE administered via the IN route was higher when compared with other groups in neurobehavioral, biochemical estimation, and gene expression studies. The results suggest that the IN route can be explored in the future for the delivery of actives via nanocolloidal carriers in the brain for neurological disorders and can serve as promising alternatives for conventional dosage forms and routes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow 226002, India.
- Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.
- Division of Biological Sciences, ICMR-National Institute of Occupational Health, Meghani Nagar, Ahmedabad, Gujarat 380016, India.
ORCID-Profile: Mayank Handa, Rabi Sankar Bhatta, Rahul Shukla
Förderung
- Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers, India
Zitieren
APA
Handa, M., Sanap, S. N., Bhatta, R. S., Patil, G. P., Palkhade, R., Singh, D. P., & Shukla, R. (2023). Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies. Molecular Pharmaceutics, 20(9), 4714-4728. https://doi.org/10.1021/acs.molpharmaceut.3c00454
Vancouver
Handa M, Sanap SN, Bhatta RS, Patil GP, Palkhade R, Singh DP, et al. Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies. Molecular Pharmaceutics. 2023;20(9):4714-4728. doi:10.1021/acs.molpharmaceut.3c00454
BibTeX
@article{Handa2023,
author = {Handa, Mayank and Sanap, Sachin Nashik and Bhatta, Rabi Sankar and Patil, Gajanan Pratap and Palkhade, Rajendra and Singh, Dhirendra Pratap and Shukla, Rahul},
title = {Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {9},
pages = {4714--4728},
doi = {10.1021/acs.molpharmaceut.3c00454}
}
EUVIMED